FRANKFURT, March 25 (Reuters) - Diversified healthcare and chemicals group Merck KGaA
Batra will succeed Robert Yates, who has decided to leave the German company to take on a new job outside of Merck, it said on Tuesday.
Uta Kemmerich-Keil, who currently heads Merck's allergy treatment unit Allergopharma, will succeed Batra to lead the Consumer Health unit, which makes non-prescription or over-the-counter (OTC) drugs and which owns the seven seas brand.
It also said that Annalisa Jenkins, the head Merck's pharmaceuticals research and development (R&D), will leave the group at the end of March. Belen Garijo, who heads Merck's pharmaceuticals division, will be in charge of R&D until a permanent successor is found.
(Reporting by Ludwig Burger; Editing by Jonathan Gould)
((ludwig.burger@thomsonreuters.com)(+49 69 7565 1311)(Reuters Messaging: ludwig.burger.thomsonreuters.com@reuters.net))
Keywords: MERCKKGAA EXECUTIVES




















